Treatment of intermittent reflux symptoms: One size does not fit all

Journal of Clinical Gastroenterology

Volumn 41, Issue 6, 2007, Pages 546-547

  DeVault, Kenneth R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROTALCITE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE;

BACTERIAL INFECTION; CLINICAL TRIAL; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIP FRACTURE; HUMAN; LIFESTYLE; LOW DRUG DOSE; PATIENT SATISFACTION; PNEUMONIA; PRIORITY JOURNAL; REMISSION; SINGLE DRUG DOSE; STOMACH ACID;

ANTACIDS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMPS;

EID: 34250710594     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31804d2399     Document Type: Editorial

References (19)

1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190-200.
2. Hungin APS, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract. 1999;49:451-453.
3. Chiba N, DeGara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798-1810.
4. Holtmeier W, Holtmann G, Caspary WF, et al. On-demand treatment of acute heartburn with the antacid hydrotalcite compared to famotidine and placebo: randomized double-blind cross-over study. J Clin Gastroenterol. 2007. In press.
5. Grove O, Bekker C, Jeppe-Hansen MG, et al. Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial. Scand J Gastroenterol. 1985;20:457-461.
6. Weberg R, Berstad A. Symptomatic effect of low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol. 1989;24:401-406.
7. Faaij R, Van Gerven J, Jolivet-Landreau I, et al. Onset of action during on-demand treatment with Maalox suspension or low-dose ranitidine for heartburn. Aliment Pharmacol Ther. 1999;13:1605-1610.
8. Washington N, Parker MA, Steele RJ, et al. Time to onset of action of sodium alginate, rantidine, omeprazole and water based on oesophageal pH [Abstract]. Gastroenterology. 1999;116:A350.
9. Johannessen T, Kristensen P. On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets. Clin Ther. 1997;19:73-81.
10. Galmiche JP, Shi G, Simon B, et al. On-demand treatment of gastrooesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Aliment Pharmacol Ther. 1998;12:909-917.
11. Wilhelmsen I, Hatlebakk JG, Olafsson S, et al. On demand therapy for reflux oesophagitis - a prospective study of symptoms, patient satisfaction and quality of life. Aliment Pharmacol Ther. 1999;13:1035-1040.
12. Miner P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover trial. Am J Gastroenterol. 2003;98:2616-2620.
13. Katz PO, Castell DO, Chen Y, et al. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther. 2004;20:399-406.
14. Howden CW. Review article: immediate-release proton-pump inhibitory therapy - potential advantages. Aliment Pharmacol Ther. 2005;22(suppl 3):25-30.
15. Scarpignato C, Pelosini I, Dimario F. Acid suppression therapy: where do we go from here? Dig Dis Sci. 2006;24:11-46.
16. Bardhan KD, Muller-Lissner S, Gibard MA, et al. Symptomatic gastroesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ. 1999;318:502-507.
17. Laheij RJF, Sturkenboom MCJM, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-1960.
18. Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989-2995.
19. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-2953.